Prelude Therapeutics Incorporated (PRLD) Stock Analysis & Investment Frameworks
Prelude Therapeutics Incorporated (PRLD) stock analysis on Invetso. Review Prelude Therapeutics Incorporated’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Prelude Therapeutics Incorporated Company Overview
- Exchange: NASDAQ Global Select
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Prelude Therapeutics Incorporated Key Financial Metrics
- Market Cap: $205.76M
- Revenue: $12.14M
- ROE: -75.35%
- ROIC: -43.74%
- Dividend Yield: N/A
About Prelude Therapeutics Incorporated
Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on identifying and developing innovative, targeted cancer treatments for patient populations with unmet medical needs. Its pipeline includes PRT543, currently undergoing Phase 1 clinical evaluation for certain solid tumors and myeloid malignancies. Another asset, PRT811, is also in Phase 1 trials, targeting various solid tumors, notably glioblastoma multiforme. The company is additionally progressing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a powerful and highly kinome-selective CDK9 inhibitor; PRT-SCA2, which is in preclinical development for several genomically selected cancers; PRT3645, a brain-penetrant molecule that precisely and effectively targets CDK4/6; and PRT-K4, another preclinical compound for solid tumors. Founded in 2016, the firm's headquarters are located in Wilmington, Delaware.